deferoxamine has been researched along with Innate Inflammatory Response in 55 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this work, we analyzed deferoxamine effects on adipose tissue fibro-inflammation during obesity induced by diet in mice." | 8.31 | Deferoxamine Interference in Fibro-inflammation: Additional Action in Control of Obese Adipose Tissue Dysfunction. ( Caria, CREP; de Morais, TR; Ferreira, APT; Gambero, A; Gotardo, EMF; Ribeiro, ML, 2023) |
| " In the present study, we investigated the role of deferoxamine (DFO), as a clinical iron chelator, in improvement of type 1 diabetes-induced cognitive dysfunction." | 7.96 | Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. ( Nahavandi, A; Zare, M; Zeinivand, M, 2020) |
| "To evaluate the efficacy of bovine lactoferrin (BLf), recombinant human lactoferrin (rHLf) and desferrioxamine against Helicobacter pylori in vitro and in mice and also to determine whether BLf or rHLf alter gastric inflammation." | 7.75 | Lactoferrin and desferrioxamine are ineffective in the treatment of Helicobacter pylori infection and may enhance H. pylori growth and gastric inflammation in mice. ( Butler, RN; Campbell, MA; Couper, RT; Huynh, HQ; Lawrence, A; Tran, CD, 2009) |
| "N-acetylcysteine plus deferoxamine treatment significantly attenuated hepatic and central nervous system oxidative damage after acute hepatic failure induced by CCl4." | 7.72 | Protective effect of N-acetylcysteine and deferoxamine on carbon tetrachloride-induced acute hepatic failure in rats. ( Andrades, M; Dal-Pizzol, F; Martins, MR; Menna-Barreto, S; Moreira, JC; Quevedo, J; Reinke, A; Ritter, C; Rocha, J, 2004) |
| "Airway inflammation is suggested to play an important role in bronchial asthma." | 5.29 | Airway inflammation induced by xanthine/xanthine oxidase in guinea pigs. ( Arai, H; Misawa, M, 1993) |
| "In this work, we analyzed deferoxamine effects on adipose tissue fibro-inflammation during obesity induced by diet in mice." | 4.31 | Deferoxamine Interference in Fibro-inflammation: Additional Action in Control of Obese Adipose Tissue Dysfunction. ( Caria, CREP; de Morais, TR; Ferreira, APT; Gambero, A; Gotardo, EMF; Ribeiro, ML, 2023) |
| " In the present study, we investigated the role of deferoxamine (DFO), as a clinical iron chelator, in improvement of type 1 diabetes-induced cognitive dysfunction." | 3.96 | Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. ( Nahavandi, A; Zare, M; Zeinivand, M, 2020) |
| " In the present study, we evaluated RAc1 nano particle effects on hyperalgesia and liver hepcidin and serum IL-1β and TNF-α expression levels during acute and chronic phases of adjuvant-induced inflammation in male rats and compared its effects with Deferoxamine." | 3.91 | Anti-hyperalgesia effect of nanchelating based nano particle, RAc1, can be mediated via liver hepcidin expression modulation during persistent inflammation. ( Houshmandi, E; Kalanaky, S; Manaheji, H; Mirjafai, S; Mohammadi, M; Nazemian, V; Zaringhalam, J, 2019) |
| " Based on evidence that excess iron may increase oxidative stress and contribute to the inflammatory response, we investigated whether deferoxamine (DFX), a potent iron chelating agent, reduces oxidative stress and inflammation in the diaphragm (DIA) muscle of mdx mice (an experimental model of DMD)." | 3.81 | Reduction of Oxidative Damage and Inflammatory Response in the Diaphragm Muscle of mdx Mice Using Iron Chelator Deferoxamine. ( de Almeida Hermes, T; de Burgos, RR; de Faria, FM; Macedo, AB; Minatel, E; Moraes, LH, 2015) |
| "To evaluate the efficacy of bovine lactoferrin (BLf), recombinant human lactoferrin (rHLf) and desferrioxamine against Helicobacter pylori in vitro and in mice and also to determine whether BLf or rHLf alter gastric inflammation." | 3.75 | Lactoferrin and desferrioxamine are ineffective in the treatment of Helicobacter pylori infection and may enhance H. pylori growth and gastric inflammation in mice. ( Butler, RN; Campbell, MA; Couper, RT; Huynh, HQ; Lawrence, A; Tran, CD, 2009) |
| "N-acetylcysteine plus deferoxamine treatment significantly attenuated hepatic and central nervous system oxidative damage after acute hepatic failure induced by CCl4." | 3.72 | Protective effect of N-acetylcysteine and deferoxamine on carbon tetrachloride-induced acute hepatic failure in rats. ( Andrades, M; Dal-Pizzol, F; Martins, MR; Menna-Barreto, S; Moreira, JC; Quevedo, J; Reinke, A; Ritter, C; Rocha, J, 2004) |
| "The iron-chelating agent deferoxamine (DF) was administered as a single dose and also daily over a prolonged period to evaluate availability of storage iron in dogs with induced anemia of inflammatory disease." | 3.66 | Anemia of inflammatory disease in the dog: availability of storage iron in inflammatory disease. ( Farver, TB; Feldman, BF; Kaneko, JJ, 1981) |
| " This substance is well absorbed orally and has been shown to enhance the excretion of ferric ion in iron loaded rats." | 2.36 | [Iron chelation. Biological significance and medical application]. ( Peter, HH, 1983) |
| "Intracerebral hemorrhage was induced by intrastriatal injection of collagenase." | 1.37 | Iron toxicity in mice with collagenase-induced intracerebral hemorrhage. ( Wang, J; Wu, H; Wu, T; Xu, X, 2011) |
| "Deferoxamine treatment 30 min before and 1 and 6 h after the SCI significantly reduced: (1) GFAP immunoreactivity, (2) neutrophil infiltration, (3) NF-kappaB activation, (4) iNOS expression, (5) nitrotyrosine and MDA formation, (6) DNA damage (methyl green pyronin staining and PAR formation and (7) apoptosis (TUNEL staining, FasL, Bax and Bcl-2 expression, S-100 expression)." | 1.36 | Modulation of inflammatory response after spinal cord trauma with deferoxamine, an iron chelator. ( Bramanti, P; Cuzzocrea, S; Emanuela, E; Galuppo, M; Mazzon, E; Paola, RD; Paterniti, I, 2010) |
| "Laryngopharyngeal or gastroesophageal reflux is associated with laryngeal airway hyperreactivity (LAH), but neither the cause-effect relationship nor the underlying mechanism has been elucidated." | 1.33 | Neural and hydroxyl radical mechanisms underlying laryngeal airway hyperreactivity induced by laryngeal acid-pepsin insult in anesthetized rats. ( Chang, SY; Ho, CY; Kou, YR; Tsai, TL, 2006) |
| "aureus infection in thigh." | 1.30 | Dual radiolabeled liposomes: biodistribution studies and localization of focal sites of infection in rats. ( Awasthi, VD; Goins, B; Klipper, R; Phillips, WT, 1998) |
| "Airway inflammation is suggested to play an important role in bronchial asthma." | 1.29 | Airway inflammation induced by xanthine/xanthine oxidase in guinea pigs. ( Arai, H; Misawa, M, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (16.36) | 18.7374 |
| 1990's | 7 (12.73) | 18.2507 |
| 2000's | 12 (21.82) | 29.6817 |
| 2010's | 21 (38.18) | 24.3611 |
| 2020's | 6 (10.91) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Aneesha, VA | 1 |
| Qayoom, A | 1 |
| Anagha, S | 1 |
| Almas, SA | 1 |
| Naresh, VK | 1 |
| Kumawat, S | 1 |
| Singh, WR | 1 |
| Sadam, A | 1 |
| Dinesh, M | 1 |
| Shyamkumar, TS | 1 |
| Sahoo, M | 1 |
| Lingaraju, MC | 1 |
| Singh, TU | 1 |
| Kumar, D | 1 |
| Di Paola, A | 1 |
| Tortora, C | 1 |
| Argenziano, M | 1 |
| Marrapodi, MM | 1 |
| Rossi, F | 1 |
| Gotardo, EMF | 1 |
| de Morais, TR | 1 |
| Ferreira, APT | 1 |
| Caria, CREP | 1 |
| Ribeiro, ML | 1 |
| Gambero, A | 1 |
| Feng, Y | 1 |
| Jia, L | 1 |
| Ma, W | 1 |
| Tian, C | 1 |
| Du, H | 1 |
| Zeinivand, M | 1 |
| Nahavandi, A | 1 |
| Zare, M | 1 |
| Shatrova, AN | 1 |
| Burova, EB | 1 |
| Kharchenko, MV | 1 |
| Smirnova, IS | 1 |
| Lyublinskaya, OG | 1 |
| Nikolsky, NN | 1 |
| Borodkina, AV | 1 |
| Oses, C | 1 |
| Olivares, B | 1 |
| Ezquer, M | 1 |
| Acosta, C | 1 |
| Bosch, P | 1 |
| Donoso, M | 1 |
| Léniz, P | 1 |
| Ezquer, F | 1 |
| Bennett, C | 1 |
| Mohammed, F | 1 |
| Álvarez-Ciara, A | 1 |
| Nguyen, MA | 1 |
| Dietrich, WD | 1 |
| Rajguru, SM | 1 |
| Streit, WJ | 1 |
| Prasad, A | 1 |
| Nazemian, V | 1 |
| Kalanaky, S | 1 |
| Manaheji, H | 1 |
| Houshmandi, E | 1 |
| Mohammadi, M | 1 |
| Zaringhalam, J | 1 |
| Mirjafai, S | 1 |
| Park, HR | 1 |
| Kamau, PW | 1 |
| Loch-Caruso, R | 1 |
| Moreno-Navarrete, JM | 1 |
| Ortega, F | 1 |
| Moreno, M | 1 |
| Serrano, M | 1 |
| Ricart, W | 1 |
| Fernández-Real, JM | 1 |
| Shvedova, AA | 1 |
| Kisin, ER | 1 |
| Murray, AR | 1 |
| Mouithys-Mickalad, A | 1 |
| Stadler, K | 1 |
| Mason, RP | 1 |
| Kadiiska, M | 1 |
| Medrano-Engay, B | 1 |
| Irun, P | 1 |
| Gervas-Arruga, J | 1 |
| Andrade-Campos, M | 1 |
| Andreu, V | 1 |
| Alfonso, P | 1 |
| Pocovi, M | 1 |
| Giraldo, P | 1 |
| Moraes, LH | 2 |
| Bollineli, RC | 1 |
| Mizobuti, DS | 1 |
| Silveira, Ldos R | 1 |
| Marques, MJ | 1 |
| Minatel, E | 2 |
| de Burgos, RR | 1 |
| Macedo, AB | 1 |
| de Almeida Hermes, T | 1 |
| de Faria, FM | 1 |
| Rodríguez-Cotto, RI | 1 |
| Ortiz-Martínez, MG | 1 |
| Jiménez-Vélez, BD | 1 |
| Wilks, MQ | 1 |
| Normandin, MD | 1 |
| Yuan, H | 1 |
| Cho, H | 1 |
| Guo, Y | 1 |
| Herisson, F | 1 |
| Ayata, C | 1 |
| Wooten, DW | 1 |
| El Fakhri, G | 1 |
| Josephson, L | 1 |
| David, V | 1 |
| Martin, A | 1 |
| Isakova, T | 1 |
| Spaulding, C | 1 |
| Qi, L | 1 |
| Ramirez, V | 1 |
| Zumbrennen-Bullough, KB | 1 |
| Sun, CC | 1 |
| Lin, HY | 1 |
| Babitt, JL | 1 |
| Wolf, M | 1 |
| Fairclough, M | 1 |
| Prenant, C | 1 |
| Ellis, B | 1 |
| Boutin, H | 1 |
| McMahon, A | 1 |
| Brown, G | 1 |
| Locatelli, P | 1 |
| Jones, AK | 1 |
| Xue, H | 1 |
| Chen, D | 1 |
| Zhong, YK | 1 |
| Zhou, ZD | 1 |
| Fang, SX | 1 |
| Li, MY | 1 |
| Guo, C | 2 |
| Kang, H | 1 |
| Yan, Y | 1 |
| Jia, P | 1 |
| Yang, K | 1 |
| Chen, H | 1 |
| Qi, J | 1 |
| Qian, N | 1 |
| Xu, X | 2 |
| Wang, F | 1 |
| Li, C | 1 |
| Guo, L | 1 |
| Deng, L | 1 |
| Huynh, HQ | 1 |
| Campbell, MA | 1 |
| Couper, RT | 1 |
| Tran, CD | 1 |
| Lawrence, A | 1 |
| Butler, RN | 1 |
| Hod, EA | 1 |
| Zhang, N | 1 |
| Sokol, SA | 1 |
| Wojczyk, BS | 1 |
| Francis, RO | 1 |
| Ansaldi, D | 1 |
| Francis, KP | 1 |
| Della-Latta, P | 1 |
| Whittier, S | 1 |
| Sheth, S | 1 |
| Hendrickson, JE | 1 |
| Zimring, JC | 1 |
| Brittenham, GM | 1 |
| Spitalnik, SL | 1 |
| Paterniti, I | 1 |
| Mazzon, E | 1 |
| Emanuela, E | 1 |
| Paola, RD | 1 |
| Galuppo, M | 1 |
| Bramanti, P | 1 |
| Cuzzocrea, S | 1 |
| Zhang, WJ | 1 |
| Wei, H | 1 |
| Frei, B | 1 |
| Wu, H | 1 |
| Wu, T | 1 |
| Wang, J | 2 |
| von Heesen, M | 1 |
| Hülser, M | 1 |
| Seibert, K | 1 |
| Scheuer, C | 1 |
| Dold, S | 1 |
| Kollmar, O | 1 |
| Wagner, M | 1 |
| Menger, MD | 1 |
| Schilling, MK | 1 |
| Moussavian, MR | 1 |
| Visser, CC | 1 |
| Voorwinden, LH | 1 |
| Crommelin, DJ | 1 |
| Danhof, M | 1 |
| de Boer, AG | 1 |
| Ritter, C | 1 |
| Reinke, A | 1 |
| Andrades, M | 1 |
| Martins, MR | 1 |
| Rocha, J | 1 |
| Menna-Barreto, S | 1 |
| Quevedo, J | 1 |
| Moreira, JC | 1 |
| Dal-Pizzol, F | 2 |
| Wood, KC | 1 |
| Hebbel, RP | 1 |
| Granger, DN | 1 |
| Pinho, RA | 1 |
| Silveira, PC | 1 |
| Silva, LA | 1 |
| Luiz Streck, E | 1 |
| F Moreira, JC | 1 |
| Tsai, TL | 1 |
| Chang, SY | 1 |
| Ho, CY | 1 |
| Kou, YR | 1 |
| Lindbom, J | 1 |
| Gustafsson, M | 1 |
| Blomqvist, G | 1 |
| Dahl, A | 1 |
| Gudmundsson, A | 1 |
| Swietlicki, E | 1 |
| Ljungman, AG | 1 |
| Yoshino, S | 1 |
| Blake, DR | 3 |
| Bacon, PA | 2 |
| Peter, HH | 1 |
| Sedgwick, AD | 1 |
| Winwood, P | 1 |
| Moore, AR | 1 |
| Al-Duaij, A | 1 |
| Willoughby, DA | 1 |
| Hall, ND | 1 |
| Dieppe, PA | 1 |
| Halliwell, B | 1 |
| Gutteridge, JM | 1 |
| Morini, PL | 1 |
| Bianchi, MA | 1 |
| Borsotti, M | 1 |
| Feldman, BF | 1 |
| Kaneko, JJ | 1 |
| Farver, TB | 1 |
| Ghio, AJ | 1 |
| Kennedy, TP | 1 |
| Rao, G | 1 |
| Cooke, CL | 1 |
| Miller, MJ | 1 |
| Hoidal, JR | 1 |
| Misawa, M | 1 |
| Arai, H | 1 |
| Silver, BJ | 1 |
| Hamilton, BD | 1 |
| Toossi, Z | 1 |
| Jurado, RL | 1 |
| Awasthi, VD | 1 |
| Goins, B | 1 |
| Klipper, R | 1 |
| Phillips, WT | 1 |
| Desroches, S | 1 |
| Biron, F | 1 |
| Berthon, G | 1 |
| Soybir, G | 1 |
| Köksoy, F | 1 |
| Ekiz, F | 1 |
| Yalçin, O | 1 |
| Fincan, K | 1 |
| Haklar, G | 1 |
| Yüksel, M | 1 |
| Ródenas, J | 1 |
| Carbonell, T | 1 |
| Mitjavila, MT | 1 |
| Brown, DM | 1 |
| Stone, V | 1 |
| Findlay, P | 1 |
| MacNee, W | 1 |
| Donaldson, K | 1 |
| Scaccabarozzi, A | 1 |
| Arosio, P | 1 |
| Weiss, G | 1 |
| Valenti, L | 1 |
| Dongiovanni, P | 1 |
| Fracanzani, AL | 1 |
| Mattioli, M | 1 |
| Levi, S | 1 |
| Fiorelli, G | 1 |
| Fargion, S | 1 |
| Sandau, KB | 1 |
| Fandrey, J | 1 |
| Brüne, B | 1 |
| Grimshaw, MJ | 1 |
| Balkwill, FR | 1 |
| Doherty, PC | 1 |
| Bowern, NA | 1 |
| Dixon, JE | 1 |
| Allan, JE | 1 |
| Hirschelmann, R | 1 |
| Bekemeier, H | 1 |
| MacDonald, RA | 1 |
| MacSween, RN | 1 |
| Pechet, GS | 1 |
3 reviews available for deferoxamine and Innate Inflammatory Response
| Article | Year |
|---|---|
Emerging Roles of the Iron Chelators in Inflammation.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Inflammation; Iron; Iron Chelating Agent | 2022 |
[Iron chelation. Biological significance and medical application].
Topics: Animals; Bacterial Infections; Catechols; Deferoxamine; Diabetes Mellitus; Enterobactin; Female; Hum | 1983 |
Iron, infections, and anemia of inflammation.
Topics: Anemia; Bacteria; Bacterial Infections; Blood Transfusion; Carrier Proteins; Conalbumin; Deferoxamin | 1997 |
52 other studies available for deferoxamine and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Topical bilirubin-deferoxamine hastens excisional wound healing by modulating inflammation, oxidative stress, angiogenesis, and collagen deposition in diabetic rats.
Topics: Animals; Antioxidants; Bilirubin; Collagen; Deferoxamine; Diabetes Mellitus, Experimental; Inflammat | 2022 |
Deferoxamine Interference in Fibro-inflammation: Additional Action in Control of Obese Adipose Tissue Dysfunction.
Topics: Adipose Tissue; Animals; Deferoxamine; Humans; Inflammation; Insulin Resistance; Liver; Mice; Mice, | 2023 |
Iron Chelator Deferoxamine Alleviates Progression of Diabetic Nephropathy by Relieving Inflammation and Fibrosis in Rats.
Topics: Animals; Deferoxamine; Diabetes Mellitus; Diabetic Nephropathies; Fibrosis; Inflammation; Iron; Iron | 2023 |
Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction.
Topics: Animals; Avoidance Learning; Brain Diseases; Cognitive Dysfunction; Deferoxamine; Diabetes Mellitus, | 2020 |
Outcomes of Deferoxamine Action on H
Topics: Apoptosis; Cell Differentiation; Cell Line; Cellular Microenvironment; Cellular Senescence; Cyclin D | 2021 |
Preconditioning of adipose tissue-derived mesenchymal stem cells with deferoxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: Potential application in the treatment of diabetic neuropathy.
Topics: Adipose Tissue; Adult; Anti-Inflammatory Agents; Apoptosis; Cell Proliferation; Cells, Cultured; Def | 2017 |
Neuroinflammation, oxidative stress, and blood-brain barrier (BBB) disruption in acute Utah electrode array implants and the effect of deferoxamine as an iron chelator on acute foreign body response.
Topics: Animals; Blood-Brain Barrier; Deferoxamine; Electrodes, Implanted; Foreign Bodies; Inflammation; Iro | 2019 |
Anti-hyperalgesia effect of nanchelating based nano particle, RAc1, can be mediated via liver hepcidin expression modulation during persistent inflammation.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Deferoxamine; Hepcidins; Humans; Hyperalges | 2019 |
Involvement of reactive oxygen species in brominated diphenyl ether-47-induced inflammatory cytokine release from human extravillous trophoblasts in vitro.
Topics: alpha-Tocopherol; Antioxidants; Cell Line; Cell Survival; Cyclic N-Oxides; Cytokines; Deferoxamine; | 2014 |
Lactoferrin gene knockdown leads to similar effects to iron chelation in human adipocytes.
Topics: Adipocytes; Adipogenesis; Biomarkers; Deferoxamine; Gene Knockdown Techniques; Humans; Inflammation; | 2014 |
ESR evidence for in vivo formation of free radicals in tissue of mice exposed to single-walled carbon nanotubes.
Topics: Animals; Antioxidants; Bronchoalveolar Lavage Fluid; Cytokines; Deferoxamine; Electron Spin Resonanc | 2014 |
Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease.
Topics: Adult; Aged; Benzoates; Biomarkers; Cytokines; Deferasirox; Deferoxamine; Female; Ferritins; Follow- | 2014 |
Effect of N-acetylcysteine plus deferoxamine on oxidative stress and inflammation in dystrophic muscle cells.
Topics: Acetylcysteine; Aldehydes; Animals; Cells, Cultured; Deferoxamine; Hydrogen Peroxide; Inflammation; | 2015 |
Reduction of Oxidative Damage and Inflammatory Response in the Diaphragm Muscle of mdx Mice Using Iron Chelator Deferoxamine.
Topics: Animals; Blotting, Western; Body Weight; Deferoxamine; Diaphragm; Female; Inflammation; Injections, | 2015 |
Organic extracts from African dust storms stimulate oxidative stress and induce inflammatory responses in human lung cells through Nrf2 but not NF-κB.
Topics: Acetylcysteine; Africa; Air Movements; Air Pollutants; Cell Line; Deferoxamine; Dust; Glutathione S- | 2015 |
Imaging PEG-like nanoprobes in tumor, transient ischemia, and inflammatory disease models.
Topics: Animals; Brain; Brain Ischemia; Carbocyanines; Cell Line, Tumor; Deferoxamine; Female; Inflammation; | 2015 |
Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.
Topics: Animals; Autoantigens; Cell Line; Collagen Type IV; Deferoxamine; Femur; Fibroblast Growth Factor-23 | 2016 |
A new technique for the radiolabelling of mixed leukocytes with zirconium-89 for inflammation imaging with positron emission tomography.
Topics: Chitosan; Copper Radioisotopes; Deferoxamine; Humans; Inflammation; Isotope Labeling; Leukocytes; Na | 2016 |
Deferoxamine ameliorates hepatosteatosis via several mechanisms in ob/ob mice.
Topics: Animals; Apoptosis Regulatory Proteins; Body Weight; Deferoxamine; Feeding Behavior; Gene Expression | 2016 |
Desferrioxamine reduces ultrahigh-molecular-weight polyethylene-induced osteolysis by restraining inflammatory osteoclastogenesis via heme oxygenase-1.
Topics: Actins; Animals; Bone Resorption; Deferoxamine; Gene Expression Regulation; Heme Oxygenase-1; Inflam | 2016 |
Lactoferrin and desferrioxamine are ineffective in the treatment of Helicobacter pylori infection and may enhance H. pylori growth and gastric inflammation in mice.
Topics: Animals; Anti-Bacterial Agents; Deferoxamine; Female; Gastric Mucosa; Helicobacter Infections; Helic | 2009 |
Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation.
Topics: Acute-Phase Reaction; Animals; Blood Preservation; Deferoxamine; Disease Models, Animal; Endotoxemia | 2010 |
Modulation of inflammatory response after spinal cord trauma with deferoxamine, an iron chelator.
Topics: Animals; Apoptosis; Blotting, Western; Deferoxamine; Immunohistochemistry; In Situ Nick-End Labeling | 2010 |
The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Chemokine CCL2; Cholesterol; Deferoxamine; Femal | 2010 |
Iron toxicity in mice with collagenase-induced intracerebral hemorrhage.
Topics: Animals; Body Weight; Cell Death; Cerebral Hemorrhage; Collagenases; Deferoxamine; Fluorescent Antib | 2011 |
Split-liver procedure and inflammatory response: improvement by pharmacological preconditioning.
Topics: Animals; Apoptosis; Cell Movement; Cytokines; Deferoxamine; Drug Therapy, Combination; Female; Glyci | 2011 |
Characterization and modulation of the transferrin receptor on brain capillary endothelial cells.
Topics: Acetylcysteine; Animals; Astrocytes; Capillaries; Cattle; Cells, Cultured; Cerebrovascular Circulati | 2004 |
Protective effect of N-acetylcysteine and deferoxamine on carbon tetrachloride-induced acute hepatic failure in rats.
Topics: Acetylcysteine; Animals; Antioxidants; Carbon Tetrachloride; Deferoxamine; Hydrocarbons; Inflammatio | 2004 |
Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice.
Topics: Allopurinol; Anemia, Sickle Cell; Animals; Bone Marrow Transplantation; Brain; Deferoxamine; Endothe | 2005 |
N-acetylcysteine and deferoxamine reduce pulmonary oxidative stress and inflammation in rats after coal dust exposure.
Topics: Acetylcysteine; Animals; Coal; Deferoxamine; Dust; Free Radicals; Inflammation; Lipid Peroxidation; | 2005 |
Neural and hydroxyl radical mechanisms underlying laryngeal airway hyperreactivity induced by laryngeal acid-pepsin insult in anesthetized rats.
Topics: Action Potentials; Ammonia; Animals; Antioxidants; Blood Pressure; Capsaicin; Deferoxamine; Electrop | 2006 |
Wear particles generated from studded tires and pavement induces inflammatory reactions in mouse macrophage cells.
Topics: Acetylcysteine; Androstadienes; Animals; Cell Line; Cell Survival; Cytokines; Deferoxamine; Free Rad | 2007 |
The effect of desferrioxamine on antigen-induced inflammation in the rat air pouch.
Topics: Air; Animals; Deferoxamine; Disease Models, Animal; Exudates and Transudates; Granulation Tissue; Im | 1984 |
Studies into the effects of the iron chelator desferrioxamine on the inflammatory process.
Topics: Animals; Anti-Inflammatory Agents; Deferoxamine; Inflammation; Leukocytes; Male; Orosomucoid; Rats; | 1984 |
Effect of a specific iron chelating agent on animal models of inflammation.
Topics: Acute Disease; Animals; Brain; Catalysis; Chronic Disease; Deferoxamine; Disease Models, Animal; Fem | 1983 |
[Comparison between serum ferritin and induced sideruria in the diagnosis of disorders of iron metabolism].
Topics: Adult; Aged; Deferoxamine; Female; Ferritins; Humans; Inflammation; Iron; Male; Metabolic Diseases; | 1981 |
Anemia of inflammatory disease in the dog: availability of storage iron in inflammatory disease.
Topics: Anemia; Animals; Biological Availability; Deferoxamine; Dog Diseases; Dogs; Female; Ferritins; Hemos | 1981 |
Complexation of iron cation by sodium urate crystals and gouty inflammation.
Topics: Chemotaxis, Leukocyte; Chlorides; Complement Activation; Crystallization; Deferoxamine; Ferric Compo | 1994 |
Airway inflammation induced by xanthine/xanthine oxidase in guinea pigs.
Topics: Administration, Inhalation; Animals; Azo Compounds; Bronchi; Bronchoconstriction; Capillary Permeabi | 1993 |
Suppression of TNF-alpha gene expression by hemin: implications for the role of iron homeostasis in host inflammatory responses.
Topics: Blood; Culture Media; Deferoxamine; Gene Expression Regulation, Neoplastic; Hemin; Homeostasis; Huma | 1997 |
Dual radiolabeled liposomes: biodistribution studies and localization of focal sites of infection in rats.
Topics: Animals; Chelating Agents; Deferoxamine; Glutathione; Image Processing, Computer-Assisted; Indium Ra | 1998 |
Aluminum speciation studies in biological fluids. Part 5. A quantitative investigation of A1(III) complex equilibria with desferrioxamine, 2,3-dihydroxybenzoic acid, Tiron, CP20 (L1), and CP94 under physiological conditions, and computer-aided assessment
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Aluminum; Animals; Body Fluids; Chelating Ag | 1999 |
The effects of free oxygen radical scavenger and platelet-activating factor antagonist agents in experimental acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Deferoxamine; Disease Models, Animal; Edema; Free Radi | 1999 |
Different roles for nitrogen monoxide and peroxynitrite in lipid peroxidation induced by activated neutrophils.
Topics: Animals; Arginine; Carrageenan; Deferoxamine; Exudates and Transudates; Granuloma; Inflammation; Lip | 2000 |
Increased inflammation and intracellular calcium caused by ultrafine carbon black is independent of transition metals or other soluble components.
Topics: Air Pollutants; Animals; Bronchoalveolar Lavage Fluid; Calcium; Carbon; Chelating Agents; Deferoxami | 2000 |
Relationship between TNF-alpha and iron metabolism in differentiating human monocytic THP-1 cells.
Topics: Binding Sites; Blotting, Northern; Cell Differentiation; Cell Line; Chelating Agents; Deferoxamine; | 2000 |
Accumulation of HIF-1alpha under the influence of nitric oxide.
Topics: Animals; Benzoates; Cell Hypoxia; Cell Line; Cobalt; Coculture Techniques; Deferoxamine; DNA-Binding | 2001 |
Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation--a potential mechanism.
Topics: Catalase; Cell Cycle Proteins; Cell Hypoxia; Chemotaxis; Dactinomycin; Deferoxamine; Dual Specificit | 2001 |
Characteristics of the inflammatory process in murine lymphocytic choriomeningitis.
Topics: Animals; Cerebrospinal Fluid; Cyclophosphamide; Deferoxamine; Free Radicals; Immunity, Cellular; Imm | 1986 |
Influence of the iron chelating agent desferrioxamine on two rat inflammatory models.
Topics: Animals; Arthritis, Experimental; Carrageenan; Deferoxamine; Edema; Inflammation; Rats; Rats, Inbred | 1986 |
Iron metabolism by reticuloendothelial cells in vitro. Physical and chemical conditions, lipotrope deficiency, and acute inflammation.
Topics: Animals; Ascorbic Acid; Cobalt; Copper; Cysteine; Dactinomycin; Deferoxamine; Dinitrophenols; Edetic | 1969 |